Sep 23, 2024
Dr. Harven DeShield is the CEO and Co-Founder of Vivacelle Bio, which is developing a nanoparticle-based treatment called VBI-S to address the underlying causes of septic shock. The treatment works by efficiently redistributing nitric oxide to help regulate blood pressure and improve organ function, reducing the need...
Sep 23, 2024
Dr. Harven DeShield is the CEO and Co-Founder of Vivacelle Bio, which is developing a nanoparticle-based treatment called VBI-S to address the underlying causes of septic shock. The treatment works by efficiently redistributing nitric oxide to help regulate blood pressure and improve organ function, reducing the need...
Mar 11, 2024
Christian Lillis, Co-Founder and CEO of the Peggy Lillis Foundation is a patient advocate in the fight against C. diff infection. Clostridium difficile is an opportunistic infection of the gut that often occurs after taking antibiotics and can lead to life-threatening complications. Christian shares his personal...
Mar 11, 2024
Christian Lillis, Co-Founder and CEO of the Peggy Lillis Foundation is a patient advocate in the fight against C. diff infection. Clostridium difficile is an opportunistic infection of the gut that often occurs after taking antibiotics and can lead to life-threatening complications. Christian shares his personal...
Jul 25, 2023
Joe Todisco, CEO of CorMedix, is developing a product that has broad spectrum activity against bacteria and fungus to impact the safety of receiving hemodialysis through a central venous catheter. With the recent acceptance by the FDA of the submission for DefenCath, CorMedix is hopeful of obtaining FDA approval...